Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Urology Reports
Erschienen in: Current Urology Reports 10/2018

01.10.2018 | New Imaging Techniques (S Rais-Bahrami and K Porter, Section Editors)

Role of Angio-Embolization for Renal Cell Carcinoma

verfasst von: Andrew J. Gunn, Anand R. Patel, Soroush Rais-Bahrami

Erschienen in: Current Urology Reports | Ausgabe 10/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

To provide the technical aspects of, clinical indications for, status of the current literature on, and emerging concepts in trans-arterial embolization (TAE) for renal cell carcinoma.

Recent Findings

TAE has been evaluated in several retrospective series as a neoadjuvant therapy prior to surgical resection of RCC to reduce tumor vascularity and minimize intra-operative blood loss. TAE has also been examined retrospectively as a neoadjuvant therapy prior to the percutaneous ablation of RCC to reduce blood loss and procedural complications. TAE can potentially palliate symptoms of RCC such as pain and hematuria. Trans-arterial chemoembolization and trans-arterial radioembolization are emerging concepts for RCC.

Summary

Although there have been no prospective, randomized trials demonstrating improved clinical or oncologic outcomes from TAE for patients with RCC, several retrospective studies have shown encouraging results.
Literatur
1.
2.
Gunn AJ, Gervais DA. Percutaneous ablation of the small renal mass: techniques and outcomes. Semin Interv Radiol. 2014;31(1):33–41.CrossRef
3.
Hinshaw JL, Lubner MG, Ziemlewicz TJ, Lee FT, Brace CL. Percutaneous tumor ablation tools: microwave, radiofrequency, or cryoablation – what should you use and why? Radiographics. 2014;34(5):1344–62.CrossRefPubMed
4.
Higgins LJ, Hong K. Renal ablation techniques: state of the art. AJR Am J Roentgenol. 2015;205(4):735–41.CrossRefPubMed
5.
Ginzburg S, Tomaszewski JJ, Kutikov A. Focal ablation therapy for renal cancer in the era of active surveillance and minimally invasive partial nephrectomy. Nat Rev Urol. 2017;14(11):669–82.CrossRefPubMed
6.
•• Talenfeld AD, Gennarelli RL, Elkin EB, Atoria CL, Durack JC, Huang WC, et al. Percutaneous ablation versus partial nephrectomy and radical nephrectomy for T1a renal cancer: a population-based analysis. Ann Intern Med. 2018; https://​doi.​org/​10.​7326/​M17-0585. Large, population-based analysis of over 4300 patients over a 52-month period which demonstrates that percutaneous ablation has similar oncologic outcomes to radical nephrectomy in T1a disease with less detrimental effects on renal function and fewer procedure-related complications.
7.
Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J Urol. 2001;166(5):1611–23.CrossRefPubMed
8.
Jayson M, Sanders H. Increased incidence of serendipitously discovered renal cell carcinoma. Urology. 1998;51(2):203–5.CrossRefPubMed
9.
Lin SP, Bierhals AJ, Lewis JS Jr. Best cases from the AFIP: metastatic renal cell carcinoma. Radiographics. 2007;27(5):1801–7.CrossRefPubMed
10.
Ramaswamy RS, Darcy MD. Arterial embolization for the treatment of renal masses and traumatic renal injuries. Tech Vasc Interv Radiol. 2016;19(3):203–10.CrossRefPubMed
11.
Goldstein HM, Medellin H, Beydoun MT, Wallace S, Ben-Menachem Y, Bracken RB, et al. Transcatheter embolization of renal cell carcinoma. Am J Roentgenol Radium Therapy, Nucl Med. 1975;123(3):557–62.CrossRef
12.
Patel IJ, Davidson JC, Nikolic B, Salazar GM, Schwartzberg MS, Walker TG, et al. Consensus guidelines for periprocedural management of coagulation status and hemostasis risk in percutaneous image-guided interventions. J Vasc Interv Radiol. 2012;23(6):727–36.CrossRefPubMed
13.
Sauk S, Zuckerman DA. Renal artery embolization. Semin Interv Radiol. 2011;28(4):396–406.CrossRef
14.
Gunn AJ, Mullenbach BJ, Poundstone MM, Gordetsky JB, Underwood ES, Rais-Bahrami S. Trans-arterial embolization of renal cell carcinoma prior to percutaneous ablation: technical aspects, institutional experience, and brief review of the literature. Curr Urol. 2018; In press
15.
Yamakado K, Nakatsuka A, Kobayashi S, Akeboshi M, Takaki H, Kariya Z, et al. Radiofrequency ablation combined with renal arterial embolization for the treatment of unresectable renal cell carcinoma larger than 3.5 cm: initial experience. Cardiovasc Intervent Radiol. 2006;29(3):389–94.CrossRefPubMed
16.
Nakasone Y, Kawanaka K, Ikeda O, Tamura Y, Yamashita Y. Sequential combination treatment (arterial embolization and percutaneous radiofrequency ablation) of inoperable renal cell carcinoma: single-center pilot study. Acta Radiol. 2012;53(4):410–4.CrossRefPubMed
17.
Mondshine RT, Owen S, Mondschein JI, Cizman B, Stavropoulos SW, Clark TW. Combination embolization and radiofrequency ablation therapy for renal cell carcinoma in the setting of coexisting arterial disease. J Vasc Interv Radiol. 2008;19(4):616–20.CrossRefPubMed
18.
• Arima K, Yamakado K, Kinbara H, Nakatsuka A, Takeda K, Sugimura Y. Percutaneous radiofrequency ablation with transarterial embolization is useful for treatment of stage 1 renal cell carcinoma with surgical risk: results at 2-year mean follow up. Int J Urol. 2007;14(7):585–90. Largest retrospective series analyzing the utility of trans-arterial embolization prior to percutaneous ablation in RCC showing technical feasibility and no hemorrhagic complications. CrossRefPubMed
19.
Tacke J, Mahnken A, Bucker A, Rohde D, Gunther RW. Nephron-sparing percutaneous ablation of a 5 cm renal cell carcinoma by superselective embolization and percutaneous RF-ablation. Rofo. 2001;173(11):980–3.CrossRefPubMed
20.
Gebauer B, Werk M, Lopez-Hanninen E, Felix R, Althaus P. Radiofrequency ablation in combination with embolization in metachronous recurrent renal cancer in solitary kidney after contralateral tumor nephrectomy. Cardiovasc Intervent Radiol. 2007;30(4):644–9.CrossRefPubMed
21.
Hall WH, McGahan JP, Link DP, de Vere White RW. Combined embolization and percutaneous ablation of a solid renal tumor. AJR Am J Roentgenol. 2000;174(6):1592–6.CrossRefPubMed
22.
Winokur RS, Pua BB, Madoff DC. Role of combined embolization and ablation in management of renal masses. Semin Interv Radiol. 2014;31(1):82–5.CrossRef
23.
Simon SD, Castle EP, Ferrigni RG, Lamm DL, Swanson SK, Novicki DE, et al. Complications of laparoscopic nephrectomy: the Mayo clinic experience. J Urol. 2004;171(4):1447–50.CrossRefPubMed
24.
Fardoun T, Chaste D, Oger E, Mathieu R, Peyronnet B, Rioux-Leclercq N, et al. Predictive factors of hemorrhagic complications after partial nephrectomy. Eur J Surg Oncol. 2014;40(1):85–9.CrossRefPubMed
25.
Montag S, Rais-Bahrami S, Seideman CA, Rastinehad AR, Vira MA, Kavoussi LR, et al. Delayed haemorrhage after laparoscopic partial nephrectomy: frequency and angiographic findings. BJU Int. 2011;107(9):1460–6.CrossRefPubMed
26.
Schwartz MJ, Smith EB, Trost DW, Vaughan ED. Renal artery embolization: clinical indications and experience from over 100 cases. BJU Int. 2007;99(4):881–6.CrossRefPubMed
27.
Reinhart HA, Ghaleb M, Davis BR. Transarterial embolization of renal tumors improves surgical outcomes: a case series. Int J Surg Case Rep. 2015;15:116–8.CrossRefPubMedPubMedCentral
28.
• Zielinski H, Szmigielski S, Petrovich Z. Comparison of preoperative embolization followed by radical nephrectomy with radical nephrectomy alone for renal cell carcinoma. Am J Clin Oncol. 2000;23(1):6–12. Retrospective analysis of pre-surgical trans-arterial embolization of RCC with a comparison to a control group matched for several clinical factors demonstrated a 5- and 10-year survival benefit for embolization. CrossRefPubMed
29.
• May M, Brookman-Amissah S, Pflanz S, Roigas J, Hoschke B, Kendel F. Pre-operative renal arterial embolization does not provide survival benefit in patient with radical nephrectomy for renal cell carcinoma. Br J Radiol. 2009;82(981):724–31. Retrospective analysis of pre-surgical embolization of RCC in 227 patients failed to show any clinical benefits to the additional procedure. CrossRefPubMed
30.
Subramanian VS, Stephenson AJ, Goldfarb DA, Fergany AF, Novick AC, Krishnamurthi V. Utility of preoperative renal artery embolization for management of renal tumors with inferior vena caval thrombi. Urology. 2009;74(1):154–9.CrossRefPubMed
31.
Schmit CH, Callstrom MR, Boorjian SA, Johnson MP, Atwell TD, Kurup AN, et al. A comparison of bleeding complications in patients undergoing percutaneous renal cryoablation using cryoprobes with and without heat-based track ablation. J Vasc Interv Radiol. 2018;29(6):874–9.CrossRefPubMed
32.
Kakarala B, Frangakis CE, Rodriguez R, Georgiades CS. Hemorrhagic complications of percutaneous cryoablation for renal tumors: results from a 7-year prospective study. Cardiovasc Intervent Radiol. 2016;39(11):1604–10.CrossRefPubMed
33.
•• Miller JM, Julien P, Wachsman A, Van Allan RJ, Friedman ML. The role of embolization in reducing complications of cryoablation in renal cell carcinoma. Clin Radiol. 2014;69(10):1045–9. Small retrospective analysis that showed a reduced rate of complications for percutaneous cryoablation in RCC if the tumor was embolized prior to the procedure. CrossRefPubMed
34.
•• Gunn AJ, Mullenbach BJ, Poundstone MM, Klimkowski S, Gordetsky JB, Underwood ES, et al. Trans-arterial embolization of renal cell carcinoma as an adjunctive therapy prior to cryoablation: a propensity score matching analysis. Diagn Interv Radiol 2018. In press. Retrospective propensity score matching analysis that failed to demonstrate an objective benefit to trans-arterial embolization prior to percutaneous cryoablation in RCC.
35.
De Mulder PH, van Herpen CM, Mulders PA. Current treatment of renal cell carcinoma. Ann Oncol. 2004;15(Suppl 4):iv319–28.PubMed
36.
• Serafin Z, Karolkiewicz M, Strzesniewski P, Lasek W, Bryczkowski M, Wolski Z. Palliative percutaneous kidney embolization with enbucrilate in patients with renal cell carcinoma: safety and symptom control. Med Sci Monit. 2007;13(Suppl 1):98–104. Largest retrospective series assessing the utility of trans-arterial embolization as a palliative approach in RCC showed improvements in both pain and hematuria. PubMed
37.
Munro NP, Woodhams S, Nawrocki JD, Fletcher MS, Thomas PJ. The role of transarterial embolization in the treatment of renal cell carcinoma. BJU Int. 2003;93(3):240–4.CrossRef
38.
Maxwell NJ, Saleem Amer N, Rogers E, Kiely D, Sweeney P, Brady AP. Renal artery embolization in the palliative treatment of renal carcinoma. Br J Radiol. 2007;80(950):96–102.CrossRefPubMed
39.
• Onishi T, Oishi Y, Suzuki Y, Asano K. Prognostic evaluation of transcatheter arterial embolization for unresectable renal cell carcinoma with distant metastasis. BJU Int. 2001;87(4):312–5. Retrospective study comparing the outcomes of trans-arterial therapy to best supportive care in patients with inoperable RCC showed good symptom control in the therapy group with a prolonged survival. CrossRefPubMed
40.
•• Karalli A, Ghaffarpour R, Axelsson R, Lundell L, Bozoki B, Brismar T, et al. Transarterial chemoembolization of renal cell carcinoma: a prospective controlled trial. J Vasc Interv Radiol. 2017;28(12):1664–72. Small, randomized, controlled study comparing trans-arterial embolization to trans-arterial chemoembolization prior to surgery in RCC. RCCs treated with chemoembolization showed more necrosis on post-procedural imaging than those treated with trans-arterial embolization. CrossRefPubMed
41.
•• Clark W, Aslan P, Patel M, Vass J, Cade D, de Silva S, et al. The RESIRT study: feasibility and dosimetry considerations of selective internal radiation therapy (SIRT) using yttrium-90 (Y-90) resin microspheres in patients with primary renal cell carcinoma (RCC). J Vasc Interv Radiol. 2017;28(2 Suppl):S164. Phase I clinical study demonstrating the safety of radioembolization in patients with RCC. CrossRef
Metadaten
Titel
Role of Angio-Embolization for Renal Cell Carcinoma
verfasst von
Andrew J. Gunn
Anand R. Patel
Soroush Rais-Bahrami
Publikationsdatum
01.10.2018
Verlag
Springer US
Erschienen in
Current Urology Reports / Ausgabe 10/2018
Print ISSN: 1527-2737
Elektronische ISSN: 1534-6285
DOI
https://doi.org/10.1007/s11934-018-0827-7

Weitere Artikel der Ausgabe 10/2018

Current Urology Reports 10/2018 Zur Ausgabe

Urothelial Cancer (S Daneshmand, Section Editor)

Enhanced Endoscopy in Bladder Cancer

New Imaging Techniques (S Rais-Bahrami and K Porter, Section Editors)

Contrast-Enhanced Transrectal Ultrasound in Focal Therapy for Prostate Cancer

New Imaging Techniques (S Rais-Bahrami and K Porter, Section Editors)

Imaging Protocols for Active Surveillance in Renal Cell Carcinoma

Prostate Cancer (S Prasad, Section Editor)

Improving the Specificity of PSA Screening with Serum and Urine Markers

Lower Urinary Tract Symptoms & Voiding Dysfunction (J Sandhu, Section Editor)

Use and Effectiveness of Antimicrobial Intravesical Treatment for Prophylaxis and Treatment of Recurrent Urinary Tract Infections (UTIs): a Systematic Review

New Imaging Techniques (S Rais-Bahrami and K Porter, Section Editors)

Approaches to Eliminate Radiation Exposure in the Management of Pediatric Urolithiasis

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

Stufenschema weist Prostatakarzinom zuverlässig nach

22.04.2024 Prostatakarzinom Nachrichten

Erst PSA-Test, dann Kallikrein-Score, schließlich MRT und Biopsie – ein vierstufiges Screening-Schema kann die Zahl der unnötigen Prostatabiopsien erheblich reduzieren: Die Hälfte der Männer, die in einer finnischen Studie eine Biopsie benötigten, hatte einen hochgradigen Tumor.

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

20.04.2024 EAU 2024 Kongressbericht

Beim chronischen Harnwegsinfekt bei Frauen wird bisher meist eine Antibiotikaprophylaxe eingesetzt. Angesichts der zunehmenden Antibiotikaresistenz erweist sich das Antiseptikum Methenamin-Hippurat als vielversprechende Alternative, so die Auswertung einer randomisierten kontrollierten Studie.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise